Generics 5

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Ursodeoxycholic acid manufacturers

5 products found

Filters

Filters

Filters , active

Country of origin : Vietnam

Clear all

5 products found

ursodeoxycholic acid

Tablets, film coated 150 mg, 300 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Vietnam
GMP approvals
EU GMP, WHO
Manufacturer #21022
This domestic generic drug manufacturer operates under European standards and EU-GMP certification. They specialize in producing over 300 high-quality medicinal products distributed throughout their region of operation. Their focus areas include the genitourinary system, musculoskeletal system, respiratory system, nervous system, and alimentary tract & metabolism. They offer various dosage forms and utilize a multinational team of experts. Key strengths include investments in modern manufacturing facilities with specialized HP Zones for high-potency drugs, a commitment to research and development, and a strategic goal of expanding exports to both Asian and EU markets.

Manufacturer usually replies in 7 days

ursodeoxycholic acid

Tablets 150 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Vietnam
GMP approvals
WHO
Manufacturer #21682

Manufacturer usually replies in 1 days

ursodeoxycholic acid

Capsules 300 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Vietnam
GMP approvals
WHO
Available for
Licensing with supply, Distribution only
Manufacturer #17771
A pharmaceutical company in Asia with over 15 years of experience is known for its innovative approach to developing prescription medications, particularly through the application of the Blue Ocean Strategy. This strategy focuses on creating unique products by leveraging modern technology, advanced packaging, and novel formulations to open new market spaces and meet unmet needs. Their product lines emphasize differentiation in a competitive market, supported by a strong track record of trust and reputation in the industry. They focus on key therapeutic areas, combining cost efficiency with high-quality standards.

Manufacturer usually replies in 6 days

Want to see all 5 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription
Ursodeoxycholic acid is a bile acid used to treat gallstones as well as to treat and prevent the progression of cystic fibrosis-related liver disorders. Suppliers of ursodeoxycholic acid market it in the form of 150mg, 250mg and 500mg oral tablets and capsules. The market for ursodeoxycholic acid is relatively competitive, populated with numerous manufacturing companies and suppliers. The largest manufacturers of ursodeoxycholic acid market globally are companies Mitsubishi Tanabe Pharma, Daewoong Chemical, and PharmaZell, Glenmark Pharmaceuticals, Dipharma Francis, Errengierre, and Grindeks. Ursodeoxycholic acid suppliers and distributors market both generic and trade name formulations of the drug. Buyers are advised that online sellers may attempt to market fraudulent versions of the drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified ursodeoxycholic acid manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform. The retail prices per 50 (250mg) tablets of ursodeoxycholic acid fall into an approximate range of 12,00 EUR to 15,00 EUR, whereas the equivalent amount of 500mg tablets cost from 25,00 EUR to 30,00 EUR.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation